Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer

Annals of Surgical Oncology

Volumn 23, Issue 2, 2016, Pages 655-662

  Downs Canner, Stephanie ^a   Magge, Deepa ^a   Ravindranathan, Roshni ^a   O’Malley, Mark E ^a   Francis, Lily ^a   Liu, Zuqiang ^a   Sheng Guo, Z ^a   Obermajer, Natasa ^a   Bartlett, David L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD11B ANTIGEN; COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; HUMANIZED COBRA VENOM FACTOR; RANTES; STAPHYLOCOCCUS AUREUS SUPERANTIGEN LIKE PROTEIN 7; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; EXOTOXIN; MESSENGER RNA; SNAKE VENOM; STAPHYLOCOCCAL EXOTOXIN 1; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; COMPLEMENT INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL SURVIVAL; COLONIC NEOPLASMS; COMPLEMENT ACTIVATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; COBRA VENOMS; COLONIC NEOPLASMS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; ELAPID VENOMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOTOXINS; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPERANTIGENS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84958182705     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4778-7     Document Type: Article

References (28)

1. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343:227–35.
2. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6:132–42.
3. Dechant M, Weisner W, Berger S, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008;68:4998–5003.
4. Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol Cancer Res. 2010;8:1453–65.
5. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30:286–92.
6. Nitta H, Murakami Y, Wada Y, et al. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014;32:1715–9.
7. Yu J, Caragine T, Chen S, Morgan BP, Frey AB, Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol. 1999;115:13–8.
8. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs). Mol Immunol. 2003;40:109–23.
9. Kempshall E, Thebault S, Morgan BP, Harris CL, Gallimore A. Complement-induced protectin: an explanation for the limitations of cell-based tumour immunotherapies. Immunol Cell Biol. 2012;90:869–71.
10. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor-cells from lytic doses of antibody and complement. Eur J Immunol. 1992;22:1207–13.
11. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce K562 cells calcium-dependent cross-protection from lysis. J Immunol. 1995;155:2203–10.
12. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.
13. Lu Y, Hu XB. C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep. 2014;32:2817–23.
14. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992;140:1039–43.
15. Corrales L, Ajona D, Rafail S, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;189:4674–83.
16. Lucas SD, Karlsson-Parra A, Nilsson B, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol. 1996;27:1329–35.
17. Ytting H, Jensenius JC, Christensen IJ, et al. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol. 2004;39:674–9.
18. Gunn L, Ding C, Liu M, et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol. 2012;189:2985–94.
19. Kempshall E, Thebault S, Morgan BP, et al. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunol Cell Biol. 2012;90:869–71.
20. Hsieh CC, Chou HS, Yang HR, et al. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood. 2013;121:1760–8.
21. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol. 2005;175:8200–8.
22. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284–90.
23. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118:5498–505.
24. Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71:7463–70.
25. Vogel CW, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon. 2010;56:1198–222.
26. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–9.
27. Magge D, Guo ZS, O’Malley ME, et al. Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Ther. 2013;20:342–50.
28. Evgin L, Acuna SA, Tanese de Souza C, et al. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015;23:1066–76.